Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 1

Status

Recruiting 3Terminated 1Completed 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5Gastrointestinal 2Sarcoma 1NET 1Gynecologic 1Endocrine 1Breast 1

Conditions

Carcinoma, Renal Cell 3Prostatic Neoplasms 2Vulvar Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Gallbladder Neoplasms 1Disease Progression 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 98Specimen Handling 79pembrolizumab 75enzalutamide 63Nivolumab 59Gemcitabine 54Docetaxel 50apalutamide 42Radiosurgery 41Abiraterone Acetate 40Androgen Antagonists 39Prednisone 38Biopsy 37darolutamide 35Cisplatin 35cabozantinib 31Radiotherapy 31Carboplatin 28Pluvicto 27abiraterone 26enfortumab vedotin 24Ipilimumab 24Radiation 23durvalumab 22atezolizumab 22Leuprolide 20olaparib 18X-Rays 18Standard of Care 18avelumab 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
tivozanib × Genitourinary × 90 days × Clear all
NCT05000294 2026-06-05

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Recruiting
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT06661720 2026-06-02

STRIKE

Alliance for Clinical Trials in Oncology

Phase 3 Recruiting
1,040 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT01885949 2026-05-20

Tivozanib + Enzalutamide in Adv Prostate Cancer

Massachusetts General Hospital

Phase 2 Terminated
5 enrolled 8 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT06053658 2026-05-20

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

M.D. Anderson Cancer Center

Phase 2 Recruiting
48 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT04987203 2026-05-08

Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

AVEO Pharmaceuticals, Inc.

Phase 3 Completed
343 enrolled
Genitourinary

Carcinoma, Renal Cell, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡